DC homeostasis in hematopoietic stem cell transplantation

被引：7

作者：

Collin, M. P. ^{[1
]}

Bogunovic, M. ^{[1
]}

Merad, M. ^{[1
]}

机构：

[1] CUNY Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY 10029 USA

来源：

CYTOTHERAPY | 2007年 / 9卷 / 06期

关键词：

stem cell transplantation; dendritic cell; homeostasis; graft versus host disease;

D O I：

10.1080/14653240701507314

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

Hematopoietic stem cell transplantation is an important experimental tool and therapeutic modality. Its efficacy and toxicity are both linked to a GvH reaction that is initiated by donor T cells recognizing recipient APC, of which DC are the most potent. In most tissues recipient DC are replaced after transplantation because they turnover rapidly from BM-derived precursors. However, in a number of sites, notably the skin, recipient DC may persist and even self-renew for many months after transplantation. Understanding the homeostasis of different APC populations and how they are related to the induction of alloreactivity may help to improve the therapeutic benefit of transplantation.

引用

页码：521 / 531

页数：11

共 130 条

[81] Dendritic cell differentiation potential of mouse monocytes:: monocytes represent immediate precursors of CD8- and CD8+ splenic dendritic cells [J].

León, B ;

del Hoyo, GM ;

Parrillas, V ;

Vargas, HH ;

Sánchez-Mateos, P ;

Longo, N ;

López-Bravo, M ;

Ardavín, C .

BLOOD, 2004, 103 (07) :2668-2676

[82] Origin of dendritic cells in peripheral lymphoid organs of mice [J].

Liu, Kang ;

Waskow, Claudia ;

Liu, Xiangtao ;

Yao, Kaihui ;

Hoh, Josephine ;

Nussenzweig, Michel .

NATURE IMMUNOLOGY, 2007, 8 (06) :578-583

[83] IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors [J].

Liu, YJ .

ANNUAL REVIEW OF IMMUNOLOGY, 2005, 23 :275-306

[84] ADOPTIVE IMMUNOTHERAPY EVALUATING ESCALATING DOSES OF DONOR LEUKOCYTES FOR RELAPSE OF CHRONIC MYELOID-LEUKEMIA AFTER BONE-MARROW TRANSPLANTATION - SEPARATION OF GRAFT-VERSUS-LEUKEMIA RESPONSES FROM GRAFT-VERSUS-HOST DISEASE [J].

MACKINNON, S ;

PAPADOPOULOS, EB ;

CARABASI, MH ;

REICH, L ;

COLLINS, NH ;

BOULAD, F ;

CASTROMALASPINA, H ;

CHILDS, BH ;

GILLIO, AP ;

KERNAN, NA ;

SMALL, TN ;

YOUNG, JW ;

OREILLY, RJ .

BLOOD, 1995, 86 (04) :1261-1268

[85] Tolerance and cancer: Mechanisms of tumor evasion and strategies for breaking tolerance [J].

Mapara, MY ;

Sykes, M .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1136-1151

[86] Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: Extinction of graft-versus-leukemia effects after conversion to full donor chimerism [J].

Mapara, MY ;

Kim, YM ;

Marx, J ;

Sykes, M .

TRANSPLANTATION, 2003, 76 (02) :297-305

[87] Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells [J].

Mapara, MY ;

Kim, YM ;

Wang, SP ;

Bronson, R ;

Sachs, DH ;

Sykes, M .

BLOOD, 2002, 100 (05) :1903-1909

[88]

Maraskovsky E, 1997, ADV EXP MED BIOL, V417, P33

[89] Donor APCs are required for maximal GVHD but not for GVL [J].

Matte, CC ;

Liu, JL ;

Cormier, J ;

Anderson, BE ;

Athanasiadis, I ;

Jain, D ;

McNiff, J ;

Shlomchik, W .

NATURE MEDICINE, 2004, 10 (09) :987-992

[90] Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells [J].

McKenna, HJ ;

Stocking, KL ;

Miller, RE ;

Brasel, K ;

De Smedt, T ;

Maraskovsky, E ;

Maliszewski, CR ;

Lynch, DH ;

Smith, J ;

Pulendran, B ;

Roux, ER ;

Teepe, M ;

Lyman, SD ;

Peschon, JJ .

BLOOD, 2000, 95 (11) :3489-3497

← 4 5 6 7 8 9 10 11 12 13 →